{"id":390072,"date":"2021-03-23T00:00:00","date_gmt":"2021-03-23T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0017-2020-biopharma-hepatocellular-carcinoma-disease-landscape-and-forecast-g7-2020\/"},"modified":"2026-03-31T10:43:42","modified_gmt":"2026-03-31T10:43:42","slug":"dlsfon0017-2020-biopharma-hepatocellular-carcinoma-disease-landscape-and-forecast-g7-2020","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0017-2020-biopharma-hepatocellular-carcinoma-disease-landscape-and-forecast-g7-2020\/","title":{"rendered":"Hepatocellular Carcinoma | Disease Landscape and Forecast | G7 | 2020"},"content":{"rendered":"<p>Hepatocellular carcinoma is a primary malignancy of the liver that commonly arises from liver cirrhosis. Nexavar (Bayer HealthCare \/ Amgen \/ Onyx) was the only drug approved for advanced disease until the 2017\/2018 approvals of Stivarga (Bayer HealthCare), Opdivo (Bristol Myers Squibb \/ Ono Pharmaceutical), Keytruda (Merck &#038; Co.), Lenvima (Eisai \/ Merck &#038; Co.), Cabometyx (Exelixis), and Cyramza (Eli Lilly) and the 2020 approvals of Tecentriq plus Avastin (Roche \/ Genentech) and Opdivo plus Yervoy (Bristol Myers Squibb \/ Ono Pharmaceutical). Driving the growth of the hepatocellular carcinoma therapy market will be the uptake of these premium-priced immune checkpoint inhibitors and their combination regimens. Because this market is still largely untapped, it offers substantial commercial potential.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>What is the current treatment landscape for hepatocellular carcinoma, and what clinical needs remain unfulfilled?<\/li>\n<li>Which drug classes are in the late-phase development pipeline, and which agents are the most promising?<\/li>\n<li>How is the drug-treatable hepatocellular carcinoma population defined, and how will drug-treatment rates change over time?<\/li>\n<li>Which emerging therapies do we forecast to enter each of the hepatocellular carcinoma market segments?<\/li>\n<li>What uptake and sales are these therapies anticipated to secure?<\/li>\n<\/ul>\n<p><strong>Content Highlights<\/strong><\/p>\n<p>Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.<\/p>\n<p>Primary research: 19 country-specific interviews with thought leaders (medical oncologists).<\/p>\n<p>Key companies: Bayer HealthCare \/ Amgen \/ Onyx, Bristol Myers Squibb \/ Ono Pharmaceutical, Merck &#038; Co., Eisai, Exelixis \/ Ipsen, Eli Lilly, Roche \/ Genentech.<\/p>\n<p>Key drugs: Nexavar, Lenvima, Stivarga, Cabometyx, Cyramza, Avastin, Tecentriq, Opdivo, Yervoy, Keytruda.<\/p>\n<p>Population segments in market forecast: Early stage, first-line intermediate stage, second-line intermediate stage, first-line advanced stage, and second-line advanced stage hepatocellular carcinoma.<\/p>\n<p>Emerging therapies: Phase III\/PR: 3 drugs; Phase II: 18 drugs; coverage of select preclinical and Phase I products.<\/p>\n<p><strong>Product Description<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast<\/em> provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Solution Enhancement<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast <\/em>will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.<\/p>\n","protected":false},"template":"","class_list":["post-390072","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hepatocellular-carcinoma","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390072","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390072\/revisions"}],"predecessor-version":[{"id":576433,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390072\/revisions\/576433"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390072"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}